A dvanced glycation end-products (AGEs) and the receptor for AGEs (RAGE) system play an important role in the development of diabetic complications. The soluble form of RAGE (sRAGE) that potentially counteracts AGEs consists of several forms, including endogenous secretory RAGE (esRAGE; a splice variant of RAGE) and cleaved-type soluble RAGE derived from cell-surface RAGE. The aim of this study was to compare sRAGE and esRAGE directly in patients with type 1 diabetes.
Introduction
Advanced glycation end-products (AGE) and their receptor (the receptor for AGE, RAGE) system play an important role in the development of diabetic vascular complications. [1] [2] [3] [4] RAGE belongs to the immunoglobulin super-family of cell surface molecules and is composed of an extracellular region containing one 'V'-type and two 'C'-type immunoglobulin domains. 5 There are three major spliced variants of RAGE: full length, N-terminally truncated and C-terminally truncated RAGE. 6, 7 The C-terminally truncated type, named "endogenous secretory RAGE (esRAGE)", has a V-domain which is essential for binding with ligands but lacks the transmembrane domain. Therefore, esRAGE is secreted extracellularly and has an activity that neutralises the actions of AGE actions. [7] [8] [9] Other forms of soluble RAGE are proteolytically cleaved from the cellular surface by the action of matrix metalloproteinases and are then shed into the bloodstream (figure 1). 10, 11 At present, two ELISA assays are commercially available for the detection of human circulating soluble RAGE: the ELISA assay for total soluble RAGE (sRAGE), using antibodies that detect total circulating soluble RAGE (a sum of esRAGE and RAGE most likely shed upon digestion by metalloproteinase action on the cellular surface); and the ELISA for esRAGE that recognises esRAGE only using polyclonal antibody raised against the unique C-terminus of the esRAGE sequence. 12 Since genetically engineered sRAGE and esRAGE may act as decoys leading to the neutralisation of the actions of AGE under experimental conditions, 3, 7, 8, [13] [14] [15] it has been speculated that human circulating soluble RAGE might counteract inflammatory reflexes triggered by RAGE ligands. However, previous studies have shown inconsistent results with respect to the associations between circulating soluble RAGE levels and diabetic complications. Some groups have reported an inverse association between circulating soluble RAGE levels and diabetic complications, [16] [17] [18] [19] while other groups showed different results. 20, 21 Previous findings regarding circulating soluble RAGE levels and diabetes have also been inconsistent. Although it seems certain that esRAGE levels are decreased in diabetes, 16, 17 findings regarding circulating total sRAGE levels in both type 1 and type 2 diabetic patients are variable. [21] [22] [23] [24] [25] In the present study, we performed a head-to-head analysis of sRAGE and esRAGE in subjects with type 1 diabetes and subjects without diabetes and examined the possible associations of sRAGE and esRAGE with carotid atherosclerosis as a predictor of cardiovascular diseases.
Research design and methods

Study population
Study subjects were recruited from outpatients at the Diabetes Clinic of Osaka University Hospital and the Osaka Police Hospital. We considered subjects eligible for inclusion when they had type 1 diabetes diagnosed by diabetologists and were between 15 and 40 years old. Patients with malignancy, connective tissue disease, liver dysfunction, renal dysfunction (serum creatinine level > 1.2 mg/dL [110 µmol/L), or apparent cardiovascular disease were excluded. Those who were taking any oral hypoglycaemic drugs, antihypertensive, antiplatelet or lipid-lowering medication at the time of the study were also excluded. In total, 130 patients (81 women and 49 men, aged 23.6+4.9 years) were enrolled in this study. All patients were treated with insulin alone and performed at least three or four daily insulin injections. The mean daily insulin dose was 0.89+0.26 units/kg. Nine patients also had hypertension, defined as blood pressure > 140/90 mmHg, and 38 had hypercholesterolaemia, defined as total cholesterol higher than 5.2 mmol/L.
As control subjects, we also enrolled 22 age-matched healthy non-diabetic individuals. After a full explanation of the study, written informed consent was obtained from each subject. The study was approved by the Ethical Committee for Human Studies at Osaka University Graduate School of Medicine.
Clinical and biochemical assessment
Each subject had a clinical history taken. Physical examination was performed, with measurement of height, weight and resting blood pressure, and electrocardiography and laboratory testing were carried out.
Fasting blood samples were collected and serum total cholesterol and high-density lipoprotein (HDL) cholesterol, serum triglyceride and glycosylated haemoglobin (HbA 1C ) levels were measured using standard laboratory protocols (SRL Inc., Tokyo, Japan).
Albumin excretion rates were measured from 24-h urine collections. Presence of retinopathy was diagnosed by ophthalmologists, based on the findings of fundoscopy. A total of four levels of retinopathy were established: (1) non-diabetic retinopathy; (2) simple diabetic retinopathy; (3) pre-proliferative diabetic retinopathy; and (4) proliferative diabetic retinopathy. Subjects were classified as smokers if they had a current smoking habit. 
Cleaved from cell surface by matrix metalloproteinases
Measurement of circulating sRAGE and esRAGE levels
To measure the concentration of human circulating sRAGE and esRAGE in serum, fasting blood samples were collected and specimens were immediately centrifuged and stored at -80°Centigrade. Measurements were performed together using the Quantikine Human RAGE immunoassay (for total sRAGE assay, RD Systems, Wiesbaden, Germany) and B-Bridge esRAGE ELISA Kit (for esRAGE assay, B-Bridge International, Sunnyvale, US). In these ELISA assays, we used undiluted serum and performed measurements following the manufacturer's instructions. The intra-assay coefficient of variation for repeated measurements ranged from 5.9% to 8.9% for sRAGE and from 3.5% to 6.7% for esRAGE. Subtracted soluble RAGE values were calculated by subtracting the circulating esRAGE values from the circulating total sRAGE values. Thus, the subtracted soluble RAGE value has been considered to be a parameter that mainly reflects the cleaved-type soluble RAGE generated by metalloproteinase action.
Measurement of IMT
To estimate early-stage atherosclerosis, ultrasonographic scanning of the carotid artery was performed. We used an echotomographic system (Toshiba, Tokyo, Japan) with an electrical liner transducer (midfrequency 8.0 MHz). The detection limit of this echo system using 8.0 MHz was 0.1 mm. Scanning of the extracranial common carotid artery, the carotid bulb and the internal carotid artery in the neck was performed bilaterally from three different longitudinal projections (i.e. anterior oblique, lateral and posterior oblique) as well as the transverse projections, as reported in our previous studies. 26, 27 The IMT, as defined by Pignoli et al., 28 was measured as follows. At each longitudinal projection, the site of the greatest thickness that included a plaque lesion was sought along the arterial walls. Three determinations of IMT were conducted at the site of the thickest point and two adjacent points (located 1 cm upstream and 1 cm downstream from the thickest point). These three determinations were averaged to form the mean IMT. The greatest value among the six mean IMTs (three from the left side and three from the right) was used as the representative value for each individual.
Two physicians conducted and recorded all scans. Another physician, who was unaware of the clinical characteristics of the subjects, performed determinations of IMT from the photographs. The reproducibility of the IMT measurements was examined by conducting another scan one week later on eight subjects. The mean difference in IMT between these two determinations was 0.01 mm and the standard deviation was 0.04 mm, demonstrating good reproducibility of repeated measurements.
Statistical analysis
Data are given as means + SD. Means or proportions for clinical characteristics were computed for diabetic and control subjects, and the data between the two groups were compared by the 2-tailed unpaired student's t-test. Differences in proportions were tested using the chi-squared test. Single linear univariate correlations (Pearson's correla-tion coefficients) and forward and backward stepwise multivariate regression analyses were performed to evaluate the relationship between circulating soluble RAGE levels and the following variables: gender, age, duration of diabetes, smoking habit, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA 1C , total cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides. Additionally, single linear univariate correlations and forward and backward stepwise multivariate regression analyses were performed to evaluate the relationship between mean IMT and the following variables: gender, age, smoking habit, BMI, SBP, DBP, HbA 1C , total cholesterol, HDL cholesterol, triglycerides, sRAGE and esRAGE.
Variables were considered for the multivariate models when their univariable p value was less than 0.05 and the F value for the inclusion and exclusion of variables was set at 2.0. These statistical analyses were performed using Stat-View statistical software (Version 5.0 for Windows; Abacus Concepts, Berkeley, CA) on a personal computer. The threshold of statistical significance was defined as p<0.05. A publicly available power/sample size calculator was used to determine the power and sample size. 29 
Results
Comparison of circulating esRAGE, total sRAGE and subtracted soluble RAGE levels
Clinical and biochemical characteristics of the study subjects are presented in table 1. HbA 1C , BMI and triglyceride levels were significantly higher in subjects with type 1 diabetes compared to non-diabetic subjects (p<0.05). There was no significant difference between the two groups in the other clinical parameters such as age, gender, current smoking habit, SBP and DBP, total and HDL cholesterol. Circulating esRAGE levels were significantly lower in type 1 diabetic subjects than in non-diabetic subjects (0.282+0.139 ng/ml vs. 0.446+0.112 ng/ml, p<0.0001). Circulating total sRAGE levels were higher in subjects with type 1 diabetes compared to non-diabetic subjects, although there was no significant difference (1.505+0.599 ng/ml vs. 1.314+0.474 ng/ml, p=0.1591). Since total sRAGE includes both esRAGE and cleaved-type soluble RAGE derived from cell surface RAGE (figure 1), we next evaluated subtracted soluble RAGE values (circulating total sRAGE values -circulating esRAGE values) in type 1 diabetic and non-diabetic subjects. Subtracted soluble RAGE values were significantly higher in type 1 diabetic subjects than in non-diabetic subjects (1.222+0.525 ng/ml vs. 0.868+0.436 ng/ml, p=0.0032).
Circulating esRAGE levels, but not sRAGE levels, are closely associated with the status of glycaemic control
Circulating esRAGE levels were inversely correlated with HbA 1C (r=-0.361, p<0.0001) in all subjects (figure 2a). In contrast, neither circulating sRAGE levels nor subtracted soluble RAGE values were correlated with HbA 1C (figures 2b, 2c ). Circulating esRAGE levels were also inversely correlated with BMI (r=-0.280, p=0.005), SBP (r=-0.171, p=0.0357), DBP (r=-0.312, p<0.0001), total cholesterol (r=-0.200, p=0.0141), triglyceride (r=-0.254, p=0.0017) and serum creatinine levels (r=0.173, p=0.0418) (table 2). A stepwise multivariate regression analysis revealed that BMI (F=2.6), DBP (F=7.8), HbA 1C (F=3.1), triglyceride (F=2.6) and serum creatinine levels (F=3.2) were independent risk factors for a low esRAGE value in all subjects. When the diabetic subjects alone were analysed, circulating esRAGE levels were still significantly correlated with BMI (r=-0.184, p=0.0368), DBP (r=-0.315, p=0.0003), total cholesterol (r=-0.199, p=0.0239) and triglyceride (r=-0.213, p=0.0154). Circulating sRAGE levels were also inversely correlated with total cholesterol (r=-0.174, p=0.0339) but there was no significant association between the subtracted soluble RAGE values and any metabolic parameters (table 2) . Although there was no association between smoking habit and esRAGE, smoking habit was closely associated with both circulating sRAGE levels and subtracted soluble RAGE values (table 2) .
Circulating esRAGE levels, but not sRAGE levels, are inversely correlated with carotid IMT Mean IMT was significantly higher in type 1 diabetic patients compared to non-diabetic subjects (0.63+0.10 vs. 0.58+0.07 mm, respectively, p=0.0218) (table 1). Mean IMT was significantly correlated with circulating esRAGE levels (r=-0.254, p=0.0015) in all subjects (figure 3a). In contrast, neither total sRAGE levels nor subtracted soluble RAGE (table 3) . When only the diabetic subjects were analysed, the inverse correlations between esRAGE and mean IMT were weakened, but there were still statistically significant correlations between them (r=-0.220, p=0.0117).
Conclusions
This is the first comparative study of total sRAGE and esRAGE as markers of disease in type 1 diabetes. In the present study, we also focused on a new parameter, subtracted soluble RAGE value, which is calculated by subtracting the circulating esRAGE value from the circulating sRAGE value. This parameter has been considered to reflect mainly the cleaved-type soluble RAGE generated by the action of metalloproteinases ( figure 1 ). In the present study, circulating total sRAGE levels were higher in patients with type 1 diabetes than in non-diabetic subjects, although there was no significant difference. In view of the findings that AGEs induce the expression of RAGE, 30 it seems that an increase of AGEs causes an elevation of circulating sRAGE levels in diabetic patients, although the previous findings regarding circulating sRAGE levels in diabetic patients are divergent (presumably due to the relatively small numbers of study subjects). [21] [22] [23] [24] [25] Subtracted soluble RAGE values were also significantly higher in type 1 diabetic subjects compared to non-diabetic subjects. This may reflect accelerated production and shedding of cell-surface RAGE in type 1 diabetes. From the results of the present study, it is likely that circulating sRAGE and esRAGE levels are distinct markers. In fact, esRAGE levels were significantly lower in type 1 diabetic subjects compared to non-diabetic subjects, which is consistent with previous reports, 12, 17 but there was no significant difference in sRAGE levels between type 1 diabetic and nondiabetic subjects. Furthermore, esRAGE levels were inversely correlated with the status of glycaemic control, but there was no correlation between sRAGE levels and the status of glycaemic control ( figure 2) . Although the number of the subjects in this study was relatively small, the power to detect the between-group difference in serum sRAGE levels at the 5% level of significance was sufficient (91.35%). The sample size was sufficient also to detect a mild association (r>0.25) with 80% power at the 5% level of significance. However, these results should be verified in further studies with larger sample size.
Although the regulatory mechanisms for alternative splicing to generate esRAGE and for proteolytic shedding of cellsurface RAGE to generate sRAGE remain unclear, our findings suggest that circulating sRAGE and esRAGE levels are not determined simply by the status of glycaemic control, Another purpose of the present study was to test whether circulating sRAGE and esRAGE can be used as markers for atherosclerosis. This study showed that circulating esRAGE levels were inversely correlated with carotid IMT, which is consistent with previous reports. [16] [17] [18] In contrast, there was no significant association between circulating sRAGE levels and IMT. There was no significant association between subtracted soluble RAGE values and IMT, either. It has been reported that esRAGE binds to AGE and neutralises the action of AGE, leading to vascular dysfunction, 7, 8, 31, 32 and that administration of a recombinant soluble form of RAGE suppresses the development of vascular disease in diabetic model animals. 3, 7, 9, 14, 33 These observations suggest that exogenously administered soluble RAGE may capture and eliminate circulating AGEs and protect vascular tissues against AGE-elicited damage by acting as a decoy receptor. However, the divergent data concerning the associations of sRAGE (or subtracted soluble RAGE values) and esRAGE with IMT observed in this study indicate that the protective effect of esRAGE against atherosclerosis may not be entirely dependent on neutralisation of toxic AGEs. The endogenous action of esRAGE as well as cleaved-type soluble RAGE remain unknown and it is possible that these forms of RAGE have different roles in the initiation and the progression of diabetic vascular disease.
There are several limitations of this study. First, this is a cross-sectional survey with a relatively small number of subjects and the associations shown in this study were statistically significant but were not very strong. Therefore, further study would be necessary to examine whether circulating esRAGE but not sRAGE levels can be a marker for the progression of atherosclerosis.
Second, it should be verified in further studies whether the subtracted soluble RAGE value is a parameter that mainly reflects cleaved-type soluble RAGE. It is known that Quantikine Human RAGE immunoassay measures the total pool of circulating RAGE using polyclonal antibodies against the whole extracellular domain, and that B-Bridge esRAGE ELISA assay detects only esRAGE protein with an antibody raised against the unique C-terminus sequence of esRAGE and does not cross-react with other forms of soluble RAGE. However, since these two methods are totally different assays, it should be experimentally verified whether simple subtraction of esRAGE values from sRAGE values assayed with these kits really reflects the concentrations of cleavedtype soluble RAGE. In addition, more recently, Hudson BI et al. have identified numerous novel RAGE splice variants through a comprehensive analysis of the RAGE gene and its splice variants in human cells and tissues. 34 Although their study has also shown that the RAGE full-length, N-terminally truncated, and C-terminally truncated (esRAGE) isoforms were the most prevalent variants and accounted for about 90% of detected transcripts in both lung and aortic smooth muscle cells, we should keep in mind that soluble RAGE concentration measured with Quantikine Human RAGE immunoassay reflects the total pool of circulating RAGE and may be influenced by the other minor forms of soluble RAGEs. Thus, the validity and accuracy of this subtracted soluble RAGE values should be verified in further studies.
Third, we should pay attention to the possibility that serum sRAGE levels are modified in the presence of albuminuria. Indeed, Humpert PM et al. reported that serum sRAGE levels, but not esRAGE levels, were independently associated with albuminuria in type 2 diabetic patients with albuminuria. 20, 35 In the present study, however, neither the serum sRAGE nor the esRAGE level was associated with albumin excretion rate (r=0.037, p>0.05 and r=-0.060, p>0.05, respectively). This discrepancy may be caused by the difference in the backgrounds of study subjects. The subjects in the former study were middle-aged and older type 2 diabetic patients with albuminuria but our subjects were young type 1 diabetic patients and thus many of them were without albuminuria. The associations between serum soluble RAGE, albuminuria and macrovascular disease should be examined in further studies.
In summary, it is likely that circulating sRAGE and esRAGE are distinct markers and that circulating esRAGE levels, but not sRAGE levels, are closely associated with the status of glycaemic control and the progression of early-stage atherosclerosis.
